NASH drugmaker Hepion to seek strategic alternatives
Hepion Pharmaceuticals said Thursday it will seek strategic alternatives to keep its Phase IIb NASH drug development program alive alongside news that its CEO has resigned “for personal reasons.”
The New Jersey biotech said it would not enroll new patients into its ASCEND-NASH clinical study until it’s “fully funded or a strategic transaction has been entered into.”
Hepion could seek an array of alternative routes: an M&A deal, reverse merger, licensing pact, assets sale or other avenue, it said. The company said it doesn’t plan to provide updates during the process.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.